GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CellSource Co Ltd (TSE:4880) » Definitions » Debt-to-EBITDA

CellSource Co (TSE:4880) Debt-to-EBITDA : 0.00 (As of Jan. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CellSource Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

CellSource Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was 円0 Mil. CellSource Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was 円0 Mil. CellSource Co's annualized EBITDA for the quarter that ended in Jan. 2024 was 円852 Mil. CellSource Co's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for CellSource Co's Debt-to-EBITDA or its related term are showing as below:

TSE:4880' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0   Med: 0.02   Max: 0.09
Current: 0.09

During the past 7 years, the highest Debt-to-EBITDA Ratio of CellSource Co was 0.09. The lowest was 0.00. And the median was 0.02.

TSE:4880's Debt-to-EBITDA is ranked better than
85.3% of 279 companies
in the Biotechnology industry
Industry Median: 1.35 vs TSE:4880: 0.09

CellSource Co Debt-to-EBITDA Historical Data

The historical data trend for CellSource Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellSource Co Debt-to-EBITDA Chart

CellSource Co Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Debt-to-EBITDA
Get a 7-Day Free Trial 0.02 0.01 - - 0.08

CellSource Co Quarterly Data
Oct18 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.16 -

Competitive Comparison of CellSource Co's Debt-to-EBITDA

For the Biotechnology subindustry, CellSource Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellSource Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CellSource Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CellSource Co's Debt-to-EBITDA falls into.



CellSource Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

CellSource Co's Debt-to-EBITDA for the fiscal year that ended in Oct. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(20.251 + 77.291) / 1303.912
=0.07

CellSource Co's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 852.348
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jan. 2024) EBITDA data.


CellSource Co  (TSE:4880) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


CellSource Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CellSource Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CellSource Co (TSE:4880) Business Description

Traded in Other Exchanges
N/A
Address
Shibuya Mitake Building, 2nd Floor, 1-19-5 Shibuya, Shibuya-ku, Tokyo, JPN, 150-0002
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.

CellSource Co (TSE:4880) Headlines

No Headlines